ClinicalTrials.gg
CompletedNCT05968612Updated Dec 26, 2023

Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets

A Phase 1 interventional study of Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet and Lumacaftor 200 mg Film-Coated Tablet Formulation in Healthy Volunteer, sponsored by Qanatpharma Canada LTD. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Qanatpharma Canada LTD · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to assess bioequivalence of lumacaftor from Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) versus the reference commercial product, Lumacaftor 200 mg /Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) in the fed state, and food-effect bioavailability of Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) in the fasted and fed state in healthy, non-smoking, male and non-pregnant female volunteers, 18 to 55 years of age, inclusive.

Read the detailed description

This single-dose, randomized, open-label, three-way crossover, three-period, three-sequence, three-treatment, single-centre, bioequivalence and food-effect study will compare lumacaftor from Lumacaftor 200 mg Film-Coated Tablet test formulation and the commercial product, Lumacaftor 200 mg/Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) under fed conditions, and food-effect bioavailability study of Lumacaftor 200 mg Film-Coated Tablet test formulation from fasted to fed state.

The products will be studied using a crossover design with 39 healthy, non-smoking male and non-pregnant female volunteers being administered an oral dose of 1 x (2 x lumacaftor 200 mg) under fasted and fed conditions and 1 x (2 x lumacaftor 200 mg/ ivacaftor 125 mg) under fed conditions. There will be at least a 14-day washout period between the study periods to avoid carry-over effects of the preceding treatments.

This study is being conducted to support development of a lumacaftor mono-substance treatment for improving cerebral blood flow.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • lumacaftor
  • cystic fibrosis transmembrane regulator-corrector
  • CFTR-corrector
  • food effect
  • healthy volunteers
  • cerebral blood flow
  • CBF
03

In context

Lead sponsor

This is the only study on the registry with Qanatpharma Canada LTD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking male and non-pregnant female volunteers, 18 years to 55 years of age, inclusive.
  2. (BMI) that is between 18.5 and 30.0 kg/m\^2, inclusive.
  3. Results of clinical laboratory tests are within the normal range or with a deviation that is not considered by the principal investigator.
  4. Ability to fast for at least 10 hours and consume a high-fat, high-calorie meal, as well as standard meals.
  5. Agree not to have a tattoo or body piercing until the end of the study.
  6. Agree not to receive the COVID-19 vaccination from 7 days prior to the first study drug dose until 7 days after the last study drug administration in the study.
  7. Female subjects of and males who are able to father children must meet the criteria defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of any diseases or conditions unless determined as not clinically significant by the Investigator.
  2. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the Investigator.
  3. Presence of any significant physical or organ abnormality as determined by the Investigator.
  4. A positive test result for any of the following: , surface antigen, , drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol breath test and cotinine. Positive pregnancy test for female subjects.
  5. Known history or presence of:

    • Alcohol abuse or dependence within one year prior to first drug administration;
    • Drug abuse or dependence;
    • or idiosyncratic reaction to lumacaftor and ivacaftor, its , and/or related substances;
    • Food allergies
    • Presence of any dietary restrictions unless deemed by the Investigator as "Not Clinically Significant".
    • Severe allergic reactions (e.g. anaphylactic reactions, angioedema).
  6. Intolerance to and/or difficulty with blood sampling through venipuncture.
  7. Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets, etc.
  8. Individuals who have donated, in the days prior to first study drug administration:

    • 50-499 mL of blood in the previous 30 days;
    • 500 mL or more in the previous 56 days.
  9. Donation of plasma by plasmapheresis within 7 days prior to first study drug administration.
  10. Individuals who have participated in another clinical trial or who received an drug within 30 days prior to first study drug administration.
  11. Females having used implanted, injected, intravaginal, or intrauterine hormonal within 6 months prior to first study drug administration.
  12. Females taking oral or transdermal hormonal contraceptives within 30 days prior to first study drug administration.
  13. Use of any enzyme-modifying drugs or products in the previous 30 days before first study drug administration.
  14. Use of any prescription medication within 14 days prior to first study drug administration (except medically acceptable contraceptive products).
  15. Use of any over-the-counter medications within 14 days prior to first study drug administration (except for medically acceptable contraceptive products).
  16. Consumption of food or beverages containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
  17. Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing.
  18. Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by Investigator.
  19. Difficulty with swallowing whole film-coated tablet.
  20. Women who are pregnant or lactating.
  21. Have had a tattoo or body piercing within 30 days prior to first study drug administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Treatment A (Test-Fed)

    Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.

    Drug: Lumacaftor 200 mg Film-Coated Tablet Formulation

  • Active comparator
    Treatment B (Reference-Fed)

    Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg/Ivacaftor 125 mg Combination Film-Coated Tablets (Orkambi®)

    Drug: Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet

  • Experimental
    Treatment C (Test-Fasted)

    Following a 10-hour overnight fasting period, subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.

    Drug: Lumacaftor 200 mg Film-Coated Tablet Formulation

Interventions

06

What researchers measure

Primary outcomes

  1. The maximal observed plasma concentration (Cmax)

    Serial blood samples for determination of study drug will be collected pre-dose at 0, and post-dose at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 24, 48, and 72 hours

    Time frame: Up to 72 hours post dose in each treatment period

  2. Area under the concentration-time curve from time zero to 72 hours (AUC72)

    Serial blood samples for determination of study drug will be collected pre-dose at 0, and post-dose at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 24, 48, and 72 hours

    Time frame: Up to 72 hours post dose in each treatment period

  3. Area under the concentration-time curve from time zero to infinity (AUCinf)

    Serial blood samples for determination of study drug will be collected pre-dose at 0, and post-dose at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 24, 48, and 72 hours

    Time frame: Up to 72 hours post dose in each treatment period

  4. Time when the maximal plasma concentration is observed (Tmax)

    Serial blood samples for determination of study drug will be collected pre-dose at 0, and post-dose at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 24, 48, and 72 hours

    Time frame: Up to 72 hours post dose in each treatment period

07

Study locations

1 site
  • BioPharma Services Inc.
    Toronto, Ontario M9L3A2, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Qanatpharma will provide access upon request to individual de-identified participant data reported in the publication beginning 12 months after publication and for up to 36 months following article publication. Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement. Contact information will be provided at the time of article publication.

Supporting information: Study protocol

Time frame: 12 months after article publication and for up to 36 months following article publication

Access criteria: Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Nov 17, 2023
Primary completionActual
Dec 18, 2023
CompletionActual
Dec 18, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05968612
Lead sponsor
Qanatpharma Canada LTD
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Nov 17, 2023
Primary completion
Dec 18, 2023
Completion
Dec 18, 2023
Last update
Dec 26, 2023

Study contacts

Isabella Szeto, MD, CCFP
principal investigator · BioPharma Service Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion